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Abstract
Chronic myelomonocytic leukemia (CMML) has recently been associated with a high incidence of diverse mutations in
genes such as TET2 or EZH2 that are implicated in epigenetic mechanisms. We have performed genome-wide DNA
methylation arrays and mutational analysis of TET2, IDH1, IDH2, EZH2 and JAK2 in a group of 24 patients with CMML. 249
genes were differentially methylated between CMML patients and controls. Using Ingenuity pathway analysis, we identified
enrichment in a gene network centered around PLC, JNK and ERK suggesting that these pathways, whose deregulation has
beenrecently described in CMML, are affected by epigenetic mechanisms. Mutations of TET2, JAK2 and EZH2 were found in
15 patients (65%), 4 patients (17%) and 1 patient (4%) respectively while no mutations in the IDH1 and IDH2 genes were
identified. Interestingly, patients with wild type TET2 clustered separately from patients with TET2 mutations, showed a
higher degree of hypermethylation and were associated with higher risk karyotypes. Our results demonstrate the presence
of aberrant DNA methylation in CMML and identifies TET2 mutant CMML as a biologically distinct disease subtype with a
different epigenetic profile.
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Introduction
Chronic myelomonocytic leukemia (CMML) is a rare clonal
hematological disorder, characterized by the neoplastic transfor-
mation of the hematopoietic stem cell [1]. Due to the clinical
presentation with either effective (myeloproliferative) or ineffective
hematopoiesis (myelodysplasia), CMML has been recently cate-
gorized in the myeloproliferative/myelodysplastic syndromes
group (MPD/MDS) of the 2008 World Health Organization
(WHO) classification [2].
Several mutations have been found in CMML patients
including RUNX1, JAK2, EZH2, CBL, TET2, ASXL1 and FLT3
genes [3,4,5,6,7,8]. In particular, as TET2 mutations are by far the
most frequently event in CMML patients [3] and as recent studies
have demonstrated that reduced function of the TET2 protein
leads to abnormal hematopoiesis and development of a CMML
like disease in mice [9,10,11] it seems that TET2 protein plays an
important role in the pathogenesis of CMML. However, data
regarding the impact of TET2 mutations on the prognosis of
CMML patients is still controversial [3,6,12].
The TET family proteins (TET1, TET2 and TET3) have been
shown to catalyze the conversion of 5-methyl-cytosine (mC) to 5-
hydroxymethyl-cytosine (hmC), a recently identified epigenetic
mark, and participate in the epigenetic regulation of gene
expression during embryogenesis and cancer [13,14,15]. These
findings point to a role of TET2 protein as part of a fine tuning
epigenetic machinery, and thus, suggest TET2 mutations as a
plausible cause for aberrant epigenetic regulation of gene
expression in CMML. Clinical studies further support this
hypothesis, as clinical responses in CMML patients to treatment
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[16,17]. However, the epigenetic profile of patients with CMML
and the relation with the presence of TET2 mutations has not
been addressed.
Genome-wide strategies offer a unique and systematic approach
to adequately establish functional and biological impact of single
gene function alterations. Therefore, the present study was
designed to establish a global methylation profiling of CMML
and to analyze the association between such DNA methylome and
the presence of TET2 as well as other mutations with potential
epigenetic impact, namely IDH1, IDH2, JAK2 and EZH2.
Materials and Methods
Samples and gene mutation analysis
Bone marrow (BM) aspirates and peripheral blood (PB)
mononuclear cells (MNC) (N=24) were collected from patients
with chronic myelomonocytic leukemia (CMML). Diagnosis of
CMML was made according to the WHO) classification system of
hematological malignancies [2,18]. Control samples included BM-
MNC (n=4) and PB-MNC (n=4) from healthy donors. Human
samples were drawn after informed consent was obtained from the
patient or the patient’s guardians in accordance with the
Declaration of Helsinki. Some of the samples were obtained more
than 15 years ago. In these cases, consent was verbal and as such
was accepted by the Research Ethics Committee. This study was
approved by the Research Ethics Committee at the University of
Navarra. Detection of JAK2V617F mutations was performed by
the ARMS technique and mutations of TET2, EZH2, exon 4 of
IDH1 (mutational hotspot at R132) and exon 4 of IDH2
(mutational hotspots at R140 and R172) by direct sequencing as
previously described [5,12,19,20,21].
DNA methylation profiling
Microarray-based DNA methylation profiling was performed
with CMML and control samples using the Human Methyla-
tion27 Beadchip (Illumina, Inc., San Diego, CA, USA)
according to the instructions of the manufacturer [22]. The
panel is developed to quantify the DNA methylation status of
27,578 CpG sites located within the proximal promoter regions
(1 kb upstream and 500 bp downstream of transcription start
sites) of 14,475 well-annotated genes from the consensus coding
sequence project as well as known cancer genes and miRNAs.
Briefly, genomic DNA was converted by sodium bisulfite
treatment and whole-genome amplified. Each CpG locus is
represented by two bead types: one for the unmethylated (U) site
and another for the methylated (M) site. After hybridization and
single-base extension using labeled nucleotides, the intensity of
the U and M beads was measured with a microarray reader.
The methylation status of a CpG was determined by the beta-
value calculation, which is based on the ratio of the fluorescent
signals between the M bead to the total locus fluorescence
intensity.
Before proceeding with methylation data analysis,
1092 CpGs located on chromosomes X and Y were excluded
to avoid biological biases, due to the known methylation-
mediated inactivation of one of the X chromosomes in female
individuals. Additionally, we evaluated the detection probabil-
ities (comparing signal intensities against background noise) for
all CpGs and excluded those with values of p.0.05 in more
than 10% of cases. From a total of 26,486 CpGs in autosomal
chromosomes, 89 CpGs showed a poor detection p value (i.e.
above 0.05) in more than 10% of cases and consequently were
eliminated from the study. Finally, 26,397 autosomal CpGs
were investigated.
Differential methylation analysis of microarray data
Initially, a global view on the DNA methylation profile of
CMML and healthy PB/BM control samples was obtained using
an unsupervised hierarchical cluster analysis including only CpGs
with standard deviation (SD) .0.25 among samples (Genesis
Software, version 1.7.5) [23]. For differential methylation analysis,
as different methods have been described in the literature and no
consensus strategy has been reached, a CpG was classified as
differentially methylated if it was detected with a combination of
the following three methods. T test: significantly differentially
methylated CpGs (dMCPG) or differentially unmethylated CpGs
(dUMCPG) were identified using a difference of at least 0.34
between mean b values of each analysis group [Db=Group A
mean b value – Group B mean b value; .0.34 (dMCPG) or
,20.34 (dUMCPG)] and a false discovery rate (FDR) below 0.05,
calculated using permutated t tests or analysis of variance if more
than two groups were compared.
Volcano analysis. A second bioinformatic analysis approach
was carried out using R and Bioconductor [24], an open source
statistical computing environment. Before statistical analysis, a
filtering process based on the methylation index (MI) value was
performed to focus the analysis on genes with large differences in
their methylation status (Fold Change: FC.1.2). Briefly, the MI
was categorized in three states: unmethylated state (MI,0.3),
methylated state (MI.0.7) and partially methylated state (MI.0.3
and ,0.7). We assigned a value of 0, 2 or 1 to each MI according
to its methylation state and these values are used for the FC
calculation. LIMMA (Linear Models for Microarray Data) [25]
was used to find out the probes that showed significant differential
methylation patterns. Genes were selected as significant using a b
statistic cut off (b.0). In addition to this study, analysis of
significant methylation changes in each sample was performed by
a Z score transformation of fold-change distributions [26]. A
threshold of |z|.1.64 (p-value,0.05) was fixed to select genes for
further analysis.
Methylation threshold analysis. A third analysis defined
differential methylation according to the following criteria: Genes
in CMML samples versus control BM/PB samples were
considered as hypermethylated when the mean b values of
controls were ,0.25 and at least a 20% of the CMML samples
had a b value .0.5. Hypomethylated genes in CMML samples
versus control BM/PB samples were considered when the mean b
values of controls were .0.75 and at least a 20% of the CMML
samples had a b value,0.5. Raw array data files were deposited in
a MIAME compliant database Gene Expression Omnibus (GEO)
and are available under the accession number GSE31600.
Bioinformatics pathway analysis
Functional enrichment analysis of Gene Ontology (GO) was
performed using differentially methylated genes between CMML
and control samples using standard hypergeometric tests [27]. All
annotations were extracted from Ensembl database (http://www.
ensembl.org). Ingenuity Pathway Analysis software was also used
to identify deregulated gene networks containing differentially
methylated genes between CMML patients and healthy controls
(Ingenuity System INC, www.ingenuity.com). Both GO and
Ingenuity pathway analyses were performed integrating the
differentially methylated genes between CMML patients and
healthy control samples coming from the three strategies utilized
(260 differentially methylated CpGs that correspond to 249
genes).
TET2 and DNA Methylation in CMML
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Analyzed genes were classified as polycomb repressive complex
2 (PRC2) targets according to the genome-wide mapping of
Polycomb target genes in embryonic stem cells (ESCs) provided by
Lee et al [28]. The proportion of PRC2-marks among differen-
tially methylated genes in CMML samples versus healthy control
samples was established. To analyze whether promoter regions of
differentially methylated genes showed different CpG composi-
tions, a recently described classification of gene promoters was
used to classify genes as having high (HCP), intermediate (ICP)
and low (LCP) CpG content [29]. Classification of the analyzed
genes was done by comparison of complete annotation lists of
PRC2-marks and promoter classes with the microarray gene list
using both gene symbol or locus link ID. To further complement
functional analysis, information about genes encoding miRNA and
small nucleolar RNA (snoRNA) was compared with the genes
included in the microarray data. A complete list of currently
known miRNA and snoRNA together with their respective host
gene (if applicable) was obtained from available databases
(miRBase, http://www.mirbase.org/; and snoRABase, http://
www-snorna.biotoul.fr/index.php). Subsequently array genes were
annotated as including miRNA or snoRNA using gene symbol ID.
DNA methylation analysis by Pyrosequencing
The methylation level of LAX1, SLC22A12 and VHL genes was
analyzed by pyrosequencing technique as previously described [30].
Primer sequences of each gene amplification conditions are
described in Table S1. Peripheral lymphocyte DNA from healthy
donors were used as negativecontrolfor methylation-specificassays.
Human male genomic DNA universally methylated for all genes
(Intergen Company, Purchase, NY) was used as a positive control
for methylated alleles. Water blanks were included with each assay.
Analysis of 5-hydroxymethylcytosine levels in specific
locus
Quantification of 5 hmC and 5 mC content in specific regions
was performed using the EpiMark 5-hmC and 5-mC analysis kit
(New England Biolabs, Ipswich, MA, USA), according to the
instructions of the manufacturer, followed by qPCR. The kit
distinguishes 5 mC from 5 hmC by the addition of glucose to the
hydroxyl group of 5 hmC utilizing T4 B-glucosyltransferase.
Briefly, 1 mg of genomic DNA was treated with 30 units of T4 B-
glucosyltransferase. Glucosylated DNA was digested with 100
units of MspI or 50 units of HpaII or no enzyme (mock digestion)
at 37uC overnight. The MspI and HpaII resistant fraction (in the
context of CCGG) was quantified by qPCR using specific primers
that covered at least one MspI/HpaII site. Resistance to digestion
with the enzyme MspI, which is blocked by glucosilated 5 hmC,
translates directly into the level of methylation in 5 hmC while
5 mC levels were obtained by subtracting the percentage of
5 hmC from the resistance to digestion with the enzyme HpaII,
which is blocked by 5 mC, 5 hmC and glucosilated 5 hmC.
Primers and conditions used to qPCR are described in the Table
S2.
Results
CMML patients have a distinct epigenetic signature
associated with increased hypermethylation of tumor
suppressor genes
Before analyzing the methylation profile of samples from
patients with CMML, we compared the methylation profile of
bone marrow and peripheral blood samples from healthy donors
in order to know whether there were differences between these two
control groups. This analysis revealed no significant differences in
methylation for any of CpG analyzed in the array, suggesting that
there are both samples are equivalent in terms of methylation
profile and can be combined.
Unsupervised analysis performed on 8 samples obtained from
healthy donors and 24 samples from patients with CMML
including all probes on the array except the probes located on
chromosome X, show that CMML samples cluster together and
separated from healthy controls, while all the control samples were
grouped together (Figure S1). The comparison of the methylation
profile between CMML and healthy donor samples using the
combination of the three different strategies (T test, Volcano
analysis and methylation threshold analysis) revealed 260 CpGs
showing a consistent differential methylation (corresponding to
249 unique genes; most detected by the methylation threshold
analysis) (Figure 1 and Table S3). Of them, 198 CpG probes
(76%) where hypermethylated in CMML (including tumor
suppressor genes such as AIM2, CDKN2A, POU4F2 or WT1) and
from these CpGs, 156 (79%) where located at CpG islands. In
contrast, 62 CpG probes (24%) where hypomethylated in CMML
(including oncogenes such as DDR2, DTL or FGF1), being 38
(61%) of them located outside of CpG islands.
The 260 differentially methylated CpGs were validated in a
second set of samples from a recently published study in which
samples from 18 CMML and 9 controls were analyzed using the
same methylation array [15]. As shown in figure S2, CMML
samples from this study cluster together and separated from
healthy controls, while all the control samples were grouped
together. Interestingly, among all CMML patients, 2 different
clusters could be identified, one with a methylation profile closer to
controls and another one with a more differentiated profile. These
results indicate that CMML features specific and distinct DNA
methylation profiles with genome-wide aberrant methylation that
occurs predominantly on promoter CpG islands.
The expression of non coding RNAs, located in intronic regions
of the genome, can be controled by the same mechanisms that
regulate its host gene so we next analyzed the methylation of non-
coding RNAs regions included in the array. Among 26,397 CpG
sites analyzed, we found 203 miRNA and mirtrons (454 probes)
and 94 snoRNAs (177 probes). The majority of these CpG were
found to be located in regions unmethylated in CMML as well as
in healthy donor samples (76% miRNA/mirtrons and 86%
snoRNAs). Two miRNAs (hsa-mir-204 and hsa-mir-153-1) were
found to be located in differentially hypermethylated regions and
one mirtron (hsa-miR-1231) in a hypomethylated region in CMML
samples when compared to healthy donor samples (Table S3).
Differentially methylated genes in CMML are implicated
in specific biologic pathways
The Gene Ontology annotation of the differentially methylated
probe sets in CMML patients revealed cell adhesion, cell
differentiation, regulation of developmental process and signal
transducer activity as pathways preferentially enriched, suggesting
an epigenetic regulation of these biological processes in CMML
patients. The Ingenuity Pathway Analysis software identified the
involvement of one particular gene network centered in PLC, JNK
and ERK pathways, suggesting their roles in the pathogenesis of
CMML [31,32] and the possibility that these pathways could be
regulated by epigenetic mechanisms (Figure 2).
Previous reports have shown that genes acquiring de novo
hypermethylation in cancer are frequently targeted by the
polycomb repressor complex 2 (PRC2) in embryonic stem cells
TET2 and DNA Methylation in CMML
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predisposed for cancer-specific hypermethylation. This phenom-
enon has been shown for several tumors such as breast, colon
cancer and lymphoma [33,34]. In order to determine whether this
was also the case in CMML, we analyzed the level of enrichment
for PRC2 targets in ESC [28] in CMML genes differentially
methylated. Twenty percent of the genes aberrantly hypermethy-
lated in CMML samples (Table S3) were PRC2 targets in ESC
(P=6 610
25 and OR: 2.2; 10.1% of the probes analyzed to the
array were PRC2 targets) indicating an enrichment in PRC2
targets among differentially hypermethylated genes in CMML.
As hypermethylation frequently targets genes with dense CpG
islands [34], we also analyzed the CpG content of differentially
methylated genes in CMML samples. Among the 13,827 genes
(26,397 CpGs) analyzed in the array 54% corresponded to high
CpG promoters (HCP), 12% to intermediate CpG (ICP) and 25%
to low CpG (LCP) [29]. We did not detect an enrichment of HCP
promoters among hypermethylated genes (59% vs. 54%) nor in
LCP promoters among hypomethylated genes (26% vs. 25%)
(Table S3) indicating the lack of selective methylation of HCP
promoters in CMML.
Mutations of TET2, JAK2, IDH1, IDH2 and EZH2 genes,
cytogenetic risk groups and methylation profile in CMML
Mutations in epigenetic genes such as JAK2, UTX, DNMT3a,
EZH2 and TET2 are a frequent events in patients with CMML
[3,5,6,35]. Based on the fact that a subgroup of CMML samples
segregated with healthy control samples while the rest of CMML
samples clustered separately in the second cohort (Figure 1 and
Figure S2) we hypothesized that mutations of JAK2, EZH2, TET2,
IDH1 or IDH2 could be implicated in the epigenetic regulation in
CMML. In order to validate our hypothesis, we analyzed the
mutations in these genes and their association with the DNA
methylation patterns observed in CMML patients.
Distribution of mutations of JAK2, EZH2, TET2, IDH1 or IDH2
genes in CMML patients are represented in Figure 1 and further
detailed in Table S4. A total of 15 out of 24 patients (65%) showed
TET2 gene mutations. In 4 patients, a JAK2V617F gene mutation
was found while only 1 patient showed a mutation of EZH2.N o
mutations in IDH1 and IDH2 genes were identified (Table S4).
Patients with wild type TET2 (TET2-wt) clustered together and
separately from mutated TET2 (TET2-mut), with TET2-wt
samples showing a higher number of differentially hypermethy-
lated genes than TET2-mut samples (Figure 1).
Comparing DNA methylation profiles between control samples
and CMML TET2-wt or TET2-mut, a total of 83 and 18
differentially methylated CpGs were identified, respectively. CpGs
differentially methylated between both TET2-wt and TET2-mut
samples compared to healthy control samples were subjected to a
second statistical analysis (as described in methods) to identify
significant methylation differences between TET2-wt and TET2-
mut groups. The analyses showed 63 CpGs differentially methyl-
Figure 1. Hierarchical cluster analysis based on abnormally methylated genes in CMML samples in comparison with healthy donor
samples. b values are depicted using a pseudocolor scale (Red=Genes hypermethylated; Green=Unmethylated genes). Samples are color coded.
The top bar beneath the dendrogram shows CMML and healthy donor samples. Second bar indicates CMML samples with or without TET2 mutation.
Third bar indicates CMML samples with or without JAK2V617F mutation. The lower bar shows the b value of JAK2 CpG analyzed in the infinium array.
doi:10.1371/journal.pone.0031605.g001
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with 13 CpGs being hypermethylated in TET2-mut CMML and
50 hypermethylated in TET2-wt samples (corresponding to 43
genes, including one miRNA, with an enrichment of PRC2 targets
in ESC: p=0.024 and OR=2.4) (Figure 3 and Table S5). The
level of methylation of 3 of the 13 genes hypermethylated in
patients with CMML TET2-mut were analyzed by pyrosequenc-
ing technology. All of them corroborated the methylation data
obtained in the array (Figure S3). Interestingly, cases with a wild
type TET2 were also associated with the presence of altered
karyotypes as compared to TET2-mut patients (p,0.01). Indeed
CMML patients with TET2-wt belonged to the recently described
high or intermediate cytogenetic risks groups [36] (4 of 6 TET2-wt
CMML patients belong to high or intermediate risk groups while
only one of 13 TET2-mut patients) (Figure 3 and Table S4).
EZH2 was found to be mutated only in one patient precluding
any further meaningful analysis of the relation between EZH2 and
methylation. EZH2 was found not to be methylated in CMML or
in healthy controls according to the results of the methylation
arrays with b values ,0.3, indicating that the methylation of the
EZH2 promoter region itself was not responsible for the differences
in methylation in CMML. JAK2V617F mutations were found in
16.6% of our CMML cohort (4 JAK2V617F and 20 JAK2 wild
type) (Table S4). Clustering analysis did not reveal any clear
relationship between JAK2 mutations and the methylation profile
(Figure 1). However, CMML patients with JAK2V617F mutation
showed 12 CpGs differentially methylated in comparison with
control samples. No differences in the methylation patterns among
JAK2V617F CMML, JAK2 wild type CMML and control samples
were detected in the unsupervised hierarchical cluster analysis
done with these 12 CpGs probes (data not shown), suggesting that
at least in CMML, the presence of JAK2V617F is not related with
a specific epigenetic profile. As it was the case for EZH2,
differences in methylation of the JAK2 promoter were not related
to the different methylation patterns observed in patients with
CMML. A b value between 0.3 and 0.7 was found in 7 healthy
donor samples and 14 CMML samples (2 of them with
JAK2V617F), a b value .0.7 in 1 CMML and 9 CMML samples
with a methylation b value ,0.3, indicating a hypomethylation of
JAK2 in these 9 cases (2 of them with JAK2V617F) (Figure 1). The
analysis of the methylation profile of CMML patients with a
hypomethylated JAK2 -which could be associated with an
Figure 2. PLC/JNK/ERK Ingenuity Pathway network containing differentially methylated genes between CMML patients and
healthy donor samples. Red: hypermethylated in CMML samples; Green: hypomethylated in CMML samples.
doi:10.1371/journal.pone.0031605.g002
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controls showed only 13 CpGs differentially methylated between
both groups which were not differentially distributed between
JAK2V617F CMML, JAK2 wild type CMML and control samples
(data not shown).
IDH1 and IDH2 were found not to be methylated in CMML or
in healthy controls according to the results of the methylation
arrays with b values ,0.2 and ,0.1 respectively, indicating that
the methylation of these two genes were not responsible for the
differences in methylation in CMML.
Differentially hypermethylated genes in TET2-mut CMML
showed a reduced content of 5 hmC and a
heterogeneity according to the region analyzed
TET2 protein has been shown to catalyze the conversion of
5 mC to 5 hmC, and patients with myeloid neoplasms have been
demonstrated to display uniformly low levels of 5 hmC [15].
However, the specific content of 5 hmC and 5 mC in genes
hypermethylated in patients with myeloid malignancies, especially
in patients in whom the gene TET2 is mutated, has not been
analyzed. To determine the 5 hmC content, we specifically
Figure 3. Analysis of differentially methylated genes in CMML samples with and without TET2 mutations. A) Hierarchical cluster analysis
based on abnormally methylated genes between CMML samples with TET2 mutations and CMML samples without TET2 mutations. B values are
depicted using a pseudocolor scale (Red=Genes hypermethylated; Green=Genes hypomethylated). Samples are color coded. The top bar beneath
the dendrogram refers CMML or healthy donor samples, second bar indicates CMML samples with or without TET2 mutations and lower bar indicates
cytogenetic risk of CMML patients. B) Box plots for hypermethylated genes in CMML samples with TET2 mutations (TET2-mut) with respect to CMML
TET2 wild type (TET2-wt) samples. C) Box plots for hypermethylated genes in CMML TET2-wt samples respect to CMML samples with TET2-mut.
doi:10.1371/journal.pone.0031605.g003
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lated in TET2-mut CMML patients. This analysis was performed
in PB samples obtained from 2 healthy donors, 8 TET2-mut and 5
TET2-wt CMML patients samples. These genes were chosen
based on the fact that only CpG dinucleotides associated to
CCGG motifs can be analyzed using MspI-HpaII enzymes. For
the LAX1 gene, we analyzed two CpG located 59upstream (238
and 2244 bp respectively) to the CpG analyzed in the
methylation array (Unique ID: cg10117369; Table S5). For
SLC22A12 one CpG upstream (59 bp) and another one down-
stream (58 bp) to the CpG analyzed in the methylation array
(Unique ID: cg07220939; Table S5) were analyzed. Finally, one
CpG downstream (5 bp) to methylation array CpG (Unique ID:
cg16869108; Table S5) was analyzed for the VHL gene. The
methylation level of the CpG located 38 bp upstream to the CpG
analyzed in the array for LAX1, a CpG 58 bp downstream for
SLC22A12 and a CpG 5 bp downstream to methylation array
CpG for VHL were analyzed by pyrosequencing showing them to
be hypermethylated in patients with TET2-mut as were the
dinucleotides analyzed in the array.
Theanalysisofthelevelof5 hmCinthedifferentCpGregionsled
to the following results: 1) the content of 5 hmC varies among
different genesregardlessofthe TET2mutational status (Figure 4);2)
changes in the percentage of 5 hmC does not affect different CpGs
equally: as shown in Figure 4, CMML patients with TET2-mut
showed lowerlevelsof5 hmCand higherlevelsof5 mCintheLAX1
and SLC22A12 CpG’s 38 bp upstream and 58 bp downstream,
respectively, of the CpG region analyzed in the methylation array
but not in the other 2 positions analyzed of the same genes. These
findings suggest that although mutation of TET2 induces a decrease
in 5 hmC content in the genome, this effect is heterogeneous
between different genes and even among specific CpG dinucleotides,
especially for those genes differentially hypermethylated.
Discussion
Despite the use of epigenetic drugs as decitabine, 5-azacitidine
or the histone deacetylase inhibitor valproic acid for the treatment
of patients with CMML [37,38,39] direct evidence for the
presence of epigenetic abnormalities in this disease has been very
limited. The presence of hypermethylation of the CDKN2B in 58%
of cases with CMML and hypomethylation of C-MYC in 2 patients
has been previously reported [40,41] and hypermethylation of 94
out of 807 genes in a small group of 14 CMML patients in
comparison with normal controls [42] are some of the few studies
reporting epigenetic changes in this disease. Our results identified
260 CpG, corresponding to 249 genes, differentially methylated in
CMML, clearly indicating that aberrant DNA methylation may
contribute to the pathogenesis of this MDS/MPN. The percentage
of hypermethylated genes is nevertheless limited in comparison
with the presence of hypermethylation in other hematological
malignancies such as B-cell lymphomas [34] or acute lympho-
blastic leukemia [30,43].
Previous studies have shown that genes frequently targeted by
the polycomb repressor complex 2 (PRC2) in ESCs are
predisposed for cancer-specific hypermethylation [33,34]. Al-
though the enrichment of PRC2 target genes among hypermethy-
lated genes in CMML was lower than in other hematological
malignancies such as lymphomas and ALL, there was a significant
enrichment in PRC2 targets, supporting this hypothesis. As
CMML is characterized by the involvement of the hematopoietic
stem cell, this result suggests that an epigenetic alteration could be
the initiating event that predisposes a precursor cell to develop-
ment of an MPN.
Ingenuity Pathway Analysis software using genes differentially
methylated between CMML and controls identified a specific gene
network centered in PLC, JNK and ERK pathways. Mice
deficient for PLC-beta3 and Lyn develop a myelodysplastic/
myeloproliferative neoplasm similar to human CMML [31,32]
which is dependent on a decrease in Shp-1 phosphatase activity
and as a consequence a constitutive activation of Stat5, required
for the development of leukemia and CMML-like syndrome [31].
The mechanism of regulation of PLC-beta3 expression in human
tumors, however, has not been described. Our analysis would
suggest a role for hypermethylation in the regulation of PLC-
beta3, at least in CMML leading to constitutive activation of
STAT5 similar to what is observed in CML and other MPN
associated with the BCR-ABL1 oncoprotein [44] or mutations of
JAK2 gene [45]. Although a link between the JNK and ERK
pathways and CMML has not been proven, activation of both
pathways plays an important role in the induction of apoptosis and
drug resistance in CML cells [46,47] and acute myeloid leukemia
[48].
More than 80% of CMML patients harbor mutations in diverse
genes including TET2, CBL, RUNX1, RAS, IDH1, IDH2, NPM1,
ASXL1, NPM1 or EZH2 [49] and although some of those
mutations like EZH2 or TET2 have been associated with the
prognosis of the disease their role is currently unclear [49]. The
limited number of patients and the frequency of mutations (65%)
only allowed us to examine in detail the correspondence between
methylation and TET2 mutations [3].
TET2 participates in the conversion of 5 mC to 5 hmC and
thus is required for DNA de-methylation [13,15,50]. Inactivation
of TET2 induces a decrease in the levels of 5 hmC in myeloid
progenitors and a dysregulation of hematopoietic stem cells
leading to the development of myeloid malignancies similar to
CMML [9,10,11]. Although TET2-mut patients would be expected
to show an increase in hypermethylation in comparison with
TET2-wt (due to the lack of capacity to convert 5 hmC) [15] this
was the case for only 13 of the differentially methylated genes
while the majority (43 genes) showed an aberrant hypermethyla-
tion in TET2-wt CMML patients. Hypermethylation could be
related to the statistically significant association between TET2-wt
patients and the presence of abnormal karyotypes (p,0.01).
Indeed, TET2-wt and abnormal karyotype have been described as
poor prognostic factors in patients with CMML [3,36].
Although recent studies have demonstrated that silencing of
TET2 protein induces a decrease in the content of 5 hmC in
normal and malignant myeloid cells [10,15], the content of 5 hmC
and 5 mC in the promoter regions (CpG regions) of genes
hypermethylated in TET2-mut patients has not been analyzed.
Our results indicate that hypermethylated genes in TET2-mut
CMML patients have a high content of 5 mC as expected from
the lack of function of TET2. However, the decrease of 5 hmC
and increase of 5 mC do not occur equally in every hypermethy-
lated gene or even in different CpGs of the same gene. On the
other hand, genes differentially methylated in TET2-wt could be
enriched both in 5 mC or 5 hmC. Some of the hypermethylated
genes in TET2-wt CMML have been directly or indirectly related
to cell cycle arrest, tumor suppression or myeloid differentiation
(ZIC1, WT1, WNK2, MRPL41, POU4F2). Whether these genes are
in fact silenced by epigenetic mechanisms should be explored in
order to determine their role in the pathogenesis of CMML.
From our results, we may conclude: 1) CMML is associated
with an abnormal epigenetic profile with 249 genes differentially
hypermethylated; 2) CMML patients with mutations in TET2
showed a different methylation profile than patients wild type
TET2, and these differences segregate CMML patients in 2 groups
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patients; 3) although TET2 mutations induced a decrease in the
content of 5 hmC, the analysis of specific genes and CpGs
demonstrate a heterogeneous behavior in terms of 5 mC and
5 hmC content. These results along with recent studies that
demonstrate the role TET2 in hematopoiesis and the development
of myeloid malignancies, suggest that epigenetic changes are not
likely the mechanism by which inactivation of the TET2 protein
induces myeloid malignancies.
Supporting Information
Figure S1 Unsupervised analysis including all probes
on the array except the probes located on chromosome
X. Samples are color coded. The top bar beneath the dendrogram
shows CMML and healthy donor samples.
(TIF)
Figure S2 Analysis of 260 differentially methylated
CpGs in CMML samples from our study and the study
from Ko et al. Hierarchical cluster analysis based on abnormally
methylated genes identified using 24 CMML patients and 8
controls, validated in another 18 CMML 9 healthy donor samples
from the study of Ko M et al. b values are depicted using a
pseudocolor scale (Red=Genes hypermethylated; Green=Genes
hypomethylated). Samples are color coded. The top bar beneath
the dendrogram refers CMML or healthy donor samples, second
bar indicates CMML samples and healthy donor samples of our
series and series of Ko et al.
(TIF)
Figure S3 Methylation results obtained by pyrose-
quencing in CMML patients samples with TET2-mut
or TET2-wt. Pyrosequencing results of analyzed CpG loci on the
array and hipermethylated in CMML TET2-mut patient samples,
corresponding to LAX1, SLC22A12 and VHL genes. In addition
one CpG located 59upstream (238) to the CpG analyzed in the
methylation array in the case of LAX1; one downstream CpG
(58 bp) in the case of SLC22A12 gene and one CpG downstream
(5 bp) in the case of VHL gene were analyzed. The values are
expressed as percentage of methylation. Median values of
percentage of DNA methylation are indicated and P values were
obtained using the 2-tailed T test or U Mann Whitney test.
(TIF)
Table S1 Specific primers and probes corresponding to
pyrosequencing analysis.
(XLS)
Table S2 Primers, probes and conditions used to
quantification of 5 hmC methylation levels by qPCR.
The CCGG location refers to the position of this motif with respect
to the analyzed CpG dinucleotide in the methylation array. All
Figure 4. Analysis of 5 hmC and 5 mC levels in genes hypermethylated in CMML TET2-mut in comparison to TET2-wt patients. The
percentage of 5 hmC, 5 mC and ratio between 5 hmC/5 mC were measured in 8 CMML TET2-mut and 5 TET2-wt patient samples using qPCR. Two
CpG located 59upstream (238 and 2244 bp respectively) to the CpG analyzed in the methylation array in the case of LAX1; one upstream CpG
(59 bp) and another downstream CpG (58 bp) to the CpG in the case of SLC22A12 gene and one CpG downstream (5 bp) in the case of VHL gene
were analyzed. Median values of percentage of 5 hmC, 5 mC or ratio between 5 hmC/5 mC are indicated and P values were obtained using the 2-
tailed T test or U Mann Whitney test. CG: CpG dinucleotide included in the array; CCGG: CpG dinucleotide in which 5 hmC and 5 mC have been
analysed and TSS: transcriptional start site.
doi:10.1371/journal.pone.0031605.g004
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FAM in 59and TAMRA in 39. In all of PCR the Tm was 60uC.
(XLS)
Table S3 Differentially methylathed genes between
CMML patient samples and healthy donor samples.
Gene Name; Red: Genes hypermethylated in CMML samples;
Green: genes hypomethylated in CMML samples. CpG ISLAND;
TRUE: probe inside in CpG island; FALSE: probe outside CpG
island. POLYCOMB; NO: no target of Polycomb group; YES:
target of Polycomb group; UD: unknown. PROMOTER CLASS:
HCP: high CpG content; ICP: intermediate CpG content; LCP:
low CpG content; UD: unknown. miRNA; NO: no annotated
miRNA in gene sequence. snoRNA; NO: no annotated snoRNA
in gene sequence.
(XLS)
Table S4 Description of Cariotype and JAK2, TET2 and
EZH2 gene mutations of CMML patients. *: High risk
Caryotype. **: Intermediate risk Caryotype. WT: wild type
sequence. UD: undetermined.
(XLS)
Table S5 Differentially methylathed genes between
TET2-wt and TET2-mut CMML patient samples. Gene
Name; Red: Genes hypermethylated in TET2-mut respect to
TET2-wt CMML samples; Green: Genes hypermethylated in
TET2-wt respect to TET2-mut CMML samples. CpG ISLAND;
TRUE: probe inside in CpG island; FALSE: probe outside CpG
island. POLYCOMB; NO: no taget of Polycomb group; YES:
target of Polycomb group; UD: unknown. PROMOTER CLASS:
HCP: high CpG content; ICP: intermediate CpG content; LCP:
low CpG content; UD: unknown. miRNA; NO: no annotated
miRNA in gene sequence. snoRNA; NO: no annotated snoRNA
in gene sequence.
(XLS)
Author Contributions
Conceived and designed the experiments: CP NCPC FP XA. Performed
the experiments: CP NMC ED MFM LG SA NCPC XA. Analyzed the
data: CP JIMS VS ED JB JSW JCC NCPC FP XA. Contributed reagents/
materials/analysis tools: SV JR MJC FP. Wrote the paper: CP FP XA.
References
1. Elliott MA (2006) Chronic neutrophilic leukemia and chronic myelomonocytic
leukemia: WHO defined. Best Pract Res Clin Haematol 19: 571–593.
2. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, et al. (2009)
The 2008 revision of the World Health Organization (WHO) classification of
myeloid neoplasms and acute leukemia: rationale and important changes. Blood
114: 937–951.
3. Kohlmann A, Grossmann V, Klein HU, Schindela S, Weiss T, et al. (2010)
Next-generation sequencing technology reveals a characteristic pattern of
molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting
frequent alterations in TET2, CBL, RAS, and RUNX1. J Clin Oncol 28:
3858–3865.
4. Levine RL, Loriaux M, Huntly BJ, Loh ML, Beran M, et al. (2005) The
JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia
and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic
lymphocytic leukemia. Blood 106: 3377–3379.
5. Ernst T, Chase AJ, Score J, Hidalgo-Curtis CE, Bryant C, et al. (2010)
Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid
disorders. Nat Genet 42: 722–726.
6. Smith AE, Mohamedali AM, Kulasekararaj A, Lim Z, Gaken J, et al. (2010)
Next-generation sequencing of the TET2 gene in 355 MDS and CMML
patients reveals low-abundance mutant clones with early origins, but indicates no
definite prognostic value. Blood 116: 3923–3932.
7. Gelsi-Boyer V, Trouplin V, Adelaide J, Bonansea J, Cervera N, et al. (2009)
Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes
and chronic myelomonocytic leukaemia. Br J Haematol 145: 788–800.
8. Lin P, Jones D, Medeiros LJ, Chen W, Vega-Vazquez F, et al. (2006) Activating
FLT3 mutations are detectable in chronic and blast phase of chronic
myeloproliferative disorders other than chronic myeloid leukemia. Am J Clin
Pathol 126: 530–533.
9. Li Z, Cai X, Cai C, Wang J, Zhang W, et al. (2011) Deletion of Tet2 in mice
leads to dysregulated hematopoietic stem cells and subsequent development of
myeloid malignancies. Blood 2011 Jul 29 [Epub ahead of print].
10. Moran-Crusio K, Reavie L, Shih A, Abdel-Wahab O, Ndiaye-Lobry D, et al.
(2011) Tet2 loss leads to increased hematopoietic stem cell self-renewal and
myeloid transformation. Cancer Cell 20: 11–24.
11. Quivoron C, Couronne L, Della Valle V, Lopez CK, Plo I, et al. (2011) TET2
Inactivation Results in Pleiotropic Hematopoietic Abnormalities in Mouse and
Is a Recurrent Event during Human Lymphomagenesis. Cancer Cell 20: 25–38.
12. Kosmider O, Gelsi-Boyer V, Cheok M, Grabar S, Della-Valle V, et al. (2009)
TET2 mutation is an independent favorable prognostic factor in myelodysplastic
syndromes (MDSs). Blood 114: 3285–3291.
13. Ito S, D’Alessio AC, Taranova OV, Hong K, Sowers LC, et al. (2010) Role of
Tet proteins in 5 mC to 5 hmC conversion, ES-cell self-renewal and inner cell
mass specification. Nature 466: 1129–1133.
14. Zhang H, Zhang X, Clark E, Mulcahey M, Huang S, et al. (2010) TET1 is a
DNA-binding protein that modulates DNA methylation and gene transcription
via hydroxylation of 5-methylcytosine. Cell Res 20: 1390–1393.
15. Ko M, Huang Y, Jankowska AM, Pape UJ, Tahiliani M, et al. (2010) Impaired
hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2.
Nature 468: 839–843.
16. Kantarjian H, Oki Y, Garcia-Manero G, Huang X, O’Brien S, et al. (2007)
Results of a randomized study of 3 schedules of low-dose decitabine in higher-
risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood
109: 52–57.
17. Oki Y, Jelinek J, Shen L, Kantarjian HM, Issa JP (2008) Induction of
hypomethylation and molecular response after decitabine therapy in patients
with chronic myelomonocytic leukemia. Blood 111: 2382–2384.
18. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, et al. (1999)
World Health Organization classification of neoplastic diseases of the
hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee
meeting-Airlie House, Virginia, November 1997. J Clin Oncol 17: 3835–3849.
19. Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, et al. (2005) Widespread
occurrence of the JAK2 V617F mutation in chronic myeloproliferative
disorders. Blood 106: 2162–2168.
20. Thol F, Weissinger EM, Krauter J, Wagner K, Damm F, et al. (2010) IDH1
mutations in patients with myelodysplastic syndromes are associated with an
unfavorable prognosis. Haematologica 95: 1668–1674.
21. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, et al. (2008) An integrated
genomic analysis of human glioblastoma multiforme. Science 321: 1807–1812.
22. Bibikova M, Le J, Barnes B, Saedinia-Melnick S, Zhou L, et al. (2009) Genome
wide DNA methylation profiling using the Infinium assay. Epigenomics 1:
177–200.
23. Sturn A, Quackenbush J, Trajanoski Z (2002) Genesis: cluster analysis of
microarray data. Bioinformatics 18: 207–208.
24. Gentleman RC, Huber W, Irizarry R, Dudoit S (2005) Bioinformatics and
Computational Biology Solutions Using R and Bioconductor. In: Heathcare S,
ed. Statistics for Biology and Health. , UK, .
25. Smyth GK (2004) Linear models and empirical bayes methods for assessing
differential expression in microarray experiments. Stat Appl Genet Mol Biol 3:
Article3.
26. Cheadle C, Vawter MP, Freed WJ, Becker KG (2003) Analysis of microarray
data using Z score transformation. J Mol Diagn 5: 73–81.
2 7 .D r a g h i c iS ,K h a t r iP ,E k l u n dA C ,S z a l l a s iZ( 2 0 0 6 )R e l i a b i l i t ya n d
reproducibility issues in DNA microarray measurements. Trends Genet 22:
101–109.
28. Lee TI, Jenner RG, Boyer LA, Guenther MG, Levine SS, et al. (2006) Control
of developmental regulators by Polycomb in human embryonic stem cells. Cell
125: 301–313.
29. Weber M, Hellmann I, Stadler MB, Ramos L, Paabo S, et al. (2007)
Distribution, silencing potential and evolutionary impact of promoter DNA
methylation in the human genome. Nat Genet 39: 457–466.
30. Vilas-Zornoza A, Agirre X, Martin-Palanco V, Martin-Subero JI, San Jose-
Eneriz E, et al. (2011) Frequent and simultaneous epigenetic inactivation of
TP53 pathway genes in acute lymphoblastic leukemia. PLoS One 6: e17012.
31. Xiao W, Ando T, Wang HY, Kawakami Y, Kawakami T (2010) Lyn- and PLC-
beta3-dependent regulation of SHP-1 phosphorylation controls Stat5 activity
and myelomonocytic leukemia-like disease. Blood 116: 6003–6013.
32. Xiao W, Hong H, Kawakami Y, Kato Y, Wu D, et al. (2009) Tumor suppression
by phospholipase C-beta3 via SHP-1-mediated dephosphorylation of Stat5.
Cancer Cell 16: 161–171.
33. Ohm JE, McGarvey KM, Yu X, Cheng L, Schuebel KE, et al. (2007) A stem
cell-like chromatin pattern may predispose tumor suppressor genes to DNA
hypermethylation and heritable silencing. Nat Genet 39: 237–242.
34. Martin-Subero JI, Kreuz M, Bibikova M, Bentink S, Ammerpohl O, et al. (2009)
New insights into the biology and origin of mature aggressive B-cell lymphomas
TET2 and DNA Methylation in CMML
PLoS ONE | www.plosone.org 9 February 2012 | Volume 7 | Issue 2 | e31605by combined epigenomic, genomic, and transcriptional profiling. Blood 113:
2488–2497.
35. Jankowska AM, Makishima H, Tiu RV, Szpurka H, Huang Y, et al. (2011)
Mutational spectrum analysis of chronic myelomonocytic leukemia includes
genes associated with epigenetic regulation: UTX, EZH2 and DNMT3A. Blood
2011 Aug 9 [Epub ahead of print].
36. Such E, Cervera J, Costa D, Sole F, Vallespi T, et al. (2010) Cytogenetic risk
stratification in chronic myelomonocytic leukemia. Haematologica 96: 375–383.
37. Costa R, Abdulhaq H, Haq B, Shadduck RK, Latsko J, et al. (2011) Activity of
azacitidine in chronic myelomonocytic leukemia. Cancer.
38. Kantarjian HM, Giles FJ, Greenberg PL, Paquette RL, Wang ES, et al. (2010)
Phase 2 study of romiplostim in patients with low- or intermediate-risk
myelodysplastic syndrome receiving azacitidine therapy. Blood 116: 3163–3170.
39. Voso MT, Santini V, Finelli C, Musto P, Pogliani E, et al. (2009) Valproic acid
at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk
myelodysplastic syndromes. Clin Cancer Res 15: 5002–5007.
40. Stephenson J, Akdag R, Ozbek N, Mufti GJ (1993) Methylation status within
exon 3 of the c-myc gene as a prognostic marker in myeloma and leukaemia.
Leuk Res 17: 291–293.
41. Tessema M, Langer F, Dingemann J, Ganser A, Kreipe H, et al. (2003)
Aberrant methylation and impaired expression of the p15(INK4b) cell cycle
regulatory gene in chronic myelomonocytic leukemia (CMML). Leukemia 17:
910–918.
42. Jiang Y, Dunbar A, Gondek LP, Mohan S, Rataul M, et al. (2009) Aberrant
DNA methylation is a dominant mechanism in MDS progression to AML.
Blood 113: 1315–1325.
43. Milani L, Lundmark A, Kiialainen A, Nordlund J, Flaegstad T, et al. (2010)
DNA methylation for subtype classification and prediction of treatment outcome
in patients with childhood acute lymphoblastic leukemia. Blood 115: 1214–1225.
44. Horita M, Andreu EJ, Benito A, Arbona C, Sanz C, et al. (2000) Blockade of the
Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells
by suppressing signal transducer and activator of transcription 5-dependent
expression of Bcl-xL. J Exp Med 191: 977–984.
45. Shannon K, Van Etten RA (2005) JAKing up hematopoietic proliferation.
Cancer Cell 7: 291–293.
46. Puissant A, Robert G, Fenouille N, Luciano F, Cassuto JP, et al. (2010)
Resveratrol promotes autophagic cell death in chronic myelogenous leukemia
cells via JNK-mediated p62/SQSTM1 expression and AMPK activation.
Cancer Res 70: 1042–1052.
47. Yang SH, Wu ZZ, Chien CM, Lo YH, Wu MJ, et al. (2008) JNK and ERK
mitogen-activated protein kinases mediate THDA-induced apoptosis in K562
cells. Cell Biol Toxicol 24: 291–302.
48. Lagadinou ED, Ziros PG, Tsopra OA, Dimas K, Kokkinou D, et al. (2008) c-Jun
N-terminal kinase activation failure is a new mechanism of anthracycline
resistance in acute myeloid leukemia. Leukemia 22: 1899–1908.
49. Grossmann V, Kohlmann A, Eder C, Haferlach C, Kern W, et al. (2011)
Molecular profiling of chronic myelomonocytic leukemia reveals diverse
mutations in .80% of patients with TET2 and EZH2 being of high prognostic
relevance. Leukemia 25: 877–879.
50. Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, et al. (2010) Leukemic
IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt
TET2 function, and impair hematopoietic differentiation. Cancer Cell 18:
553–567.
TET2 and DNA Methylation in CMML
PLoS ONE | www.plosone.org 10 February 2012 | Volume 7 | Issue 2 | e31605